Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET/CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clini[...]
The field of nuclear medicine has evolved rapidly in recent years, and one very important aspect of this progress has been the introduction of hybrid imaging systems. PET-CT has already gained widespread acceptance in many clinical settings, especially within oncology, and now SPECT-CT promises to e[...]
PET-CT is increasingly being employed in the diagnosis of both oncological and non-oncological patients, yet nuclear medicine physicians may have only limited practical experience of rare diseases and may experience difficulty in recognizing and interpreting rare findings. This unique atlas document[...]